Sanofi (SNYNF)
OTCMKTS
· Delayed Price · Currency is USD
110.33
0.00 (0.00%)
Mar 31, 2025, 4:00 PM EST
Sanofi Revenue
In the year 2024, Sanofi had annual revenue of 44.29B EUR with 7.73% growth. Sanofi had revenue of 11.42B in the quarter ending December 31, 2024.
Revenue
44.29B EUR
Revenue Growth
+7.73%
P/S Ratio
n/a
Revenue / Employee
534.35K EUR
Employees
82,878
Market Cap
134.84B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 44.29B | 3.18B | 7.73% |
| Dec 31, 2023 | 41.11B | 805.00M | 2.00% |
| Dec 31, 2022 | 40.30B | 1.13B | 2.88% |
| Dec 31, 2021 | 39.18B | 1.81B | 4.83% |
| Dec 31, 2020 | 37.37B | -262.00M | -0.70% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.76B |
| SS Innovations International | 16.04M |
| Veradigm | 588.02M |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 200.90M |
| Northwest Biotherapeutics | 1.60M |
| Silence Therapeutics | 43.26M |
| American Oncology Network | 1.76B |
Sanofi News
- 3 days ago - Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors - GlobeNewsWire
- 3 days ago - Sanofi gets FDA nod for its hemophilia treatment - Seeking Alpha
- 3 days ago - US FDA approves Sanofi's bleeding disorder therapy - Reuters
- 3 days ago - AbbVie Vs. Sanofi: Which Is The Better Investment Right Now - Seeking Alpha
- 4 days ago - Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD - GlobeNewsWire
- 5 days ago - Sanofi’s chief digital officer says remote work means employees lose the ‘serendipity’ needed to innovate - Fortune
- 6 days ago - Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA - GlobeNewsWire
- 6 days ago - Sanofi gets priority review for its multiple sclerosis treatment by FDA - Seeking Alpha